CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (Nasdaq: CRSP) announced its senior management will participate in two upcoming investor conferences in August 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CRISPR Therapeutics (Nasdaq: CRSP) announced its senior management will participate in two upcoming investor conferences in August 2020. The William Blair Biotech Focus Conference is scheduled for August 6 at 1:00 p.m. ET, while the Canaccord Genuity 40th Annual Growth Conference will take place on August 13 at 2:30 p.m. ET. Live webcasts of these events will be available on the company's website, with archives accessible for 14 days post-presentation. CRISPR Therapeutics focuses on developing gene-based medicines utilizing its innovative CRISPR/Cas9 platform.
Details
News Market Reaction – CRSP
The recorded move for CRSP in the trading session of this news was +0.97%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland and CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in August:
William Blair Biotech Focus Conference
Date: Thursday, August 6, 2020
Panel: 1:00 p.m. ET
Canaccord Genuity 40th Annual Growth Conference
Date: Thursday, August 13, 2020
Fireside chat: 2:30 p.m. ET
A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com
Media Contact:
Rachel Eides
WCG on behalf of CRISPR
+1-617-337-4167
reides@wcgworld.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.